Stifel Elevates Revolution Medicines Price Target to $170 Amid Investor Optimism
Stifel has raised its price target on Revolution Medicines (NASDAQ: RVMD) substantially to $170 from $85, underscoring strong confidence in the biotech firm's long-term revenue prospects and pipeline value. This new valuation indicates significant upside from the current share price, reflecting increased M&A interest and promising clinical data, de…